Project: A new therapeutic approach for severe bleeding

To develop a new treatment of severe bleeding to be used as prophylaxis or on demand. This innovative treatment, given systemically, prolongs the half-life of activated clotting factors at the site(s) of injury by neutralizing the main inhibitor of clotting in the blood, antithrombin III (AT). We will deliver 1) a humanized monoclonal antibody inhibiting AT; 2) cell lines producing the antibody; and 3) proof of concept for efficacy of the antibody in an animal model for severe bleeding.

Acronym ANTITHAB (Reference Number: 9763)
Duration 01/04/2015 - 01/04/2018
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 3

Project partner

Number Name Role Country
21608 Prothix BV Coordinator Netherlands
21610 Antitope Ltd Partner United Kingdom
21611 University Medical Center Utrecht Partner Netherlands
21612 GenOway Partner France
23804 Aristi Biotech BV Partner Netherlands